Saiz demonstrated that anti-CD19 CAR-T therapy for relapsed/refractory ALL resulted in a significantly higher complete response rate than donor lymphocyte infusion, highlighting its superior effectiveness in this cohort (90). Here, CD19 is linked to acute lymphoblastic leukemia.